Advertisement
Atrogi announces Phase 1a/b data

Atrogi has announced the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D).
“This full phase 1a/b data readout is exactly what we were aiming for, with primary and secondary safety-endpoints met. This puts us in a strong position to progress our ground-breaking small molecule compound ATR-258 into a larger multi-centre Phase II trial later this year, underpinned with an upcoming Series B financing. We strongly believe that our novel approach could become a transformative treatment for T2D patients,” says Atrogi’s CEO, Alexandra Ekman Ryding.
This clinical trial, conducted on both healthy volunteers and individuals with T2D, underscores the safety of ATR-258 as a novel β2-adrenoceptor agonist, offering a revolutionary approach to type 2 diabetes treatment, states the company. The mechanism of action of ATR-258 enables the selective modulation of specific positive intracellular signaling pathways. This approach makes it possible to address the core issue of type 2 diabetes, effectively reversing it to healthy levels as demonstrated in preclinical studies, the company states further.
“These safety results strongly validate my long-held vision for a more holistic treatment for diabetes that not only treats the underlying cause but also supports overall health and quality of life. It underscores the therapeutic value of this novel pathway for the treatment of type 2 diabetes. Notably, in the final cohort of people with T2D we had been specifically looking for cardiovascular safety, which is now confirmed,” says Atrogi´s founder and CSO, Professor Tore Bengtsson.
The ATTRACTIVE 1 trial
The ‘ATTRACTIVE 1’ trial, conducted in Mannheim, Germany, by Clinical Research Services (CRS), was a double-blind, placebo-controlled, randomized trial evaluating the safety of ATR-258 for the treatment of T2D. The complete trial investigated the use of single, and multiple, ascending doses of ATR-258 in 46 healthy volunteers as well as its administration at a fixed dose in 23 T2D patients over 28 days. The final data demonstrated that ATR-258 was safe and well tolerated in healthy volunteers, and importantly, also in the T2D patients.
Photo of Alexandra Ekman Ryding: Atrogi
Updated: September 16, 2024, 08:34 am
Published: March 14, 2024